ORIENT‐31 showed the benefit of sintilimab plus bevacizumab biosimilar plus chemotherapy in patients with EGFR‐mutated NSCLC who progressed on treatment with tyrosine‐kinase inhibitors [22]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.